Encochleated Oral Amphotericin for Cryptococcal Meningitis Trial 3 (EnACT3)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Contact
Study Contact
- Name: Theresa Matkovits, PhD
- Phone Number: 908-505-0975
- Email: tmatkovits@matinasbiopharma.com
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- CSF cryptococcal antigen (CrAg) positive meningitis
- Ability and willingness to provide informed consent
- Willing to receive protocol-specified lumbar punctures
Exclusion Criteria:
- Glasgow Coma Scale < 15 at time of consent
- Received >= 3 doses of amphotericin B within prior 30 days
- Inability to take enteral (oral or nasogastric) medicine
- Cannot or unlikely to attend regular clinic visits
- Receiving chemotherapy or corticosteroids
- Suspected paradoxical immune reconstitution inflammatory syndrome (IRIS)
- Pregnancy or breastfeeding
- Previous administration of MAT2203
- Any condition for which participation would not be in the best interest of the participant or that could limit protocol specified assessments
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: MAT2203 Induction / MAT2203 Consolidation
2 days IV Amphotericin B (AMB) + flucytosine (5FC) followed by oral MAT2203 + 5FC for 12 days of induction therapy followed by MAT2203 +fluconazole for 4 weeks of consolidation therapy
|
oral lipid nanocrystal amphotericin B
Other Names:
|
|
Experimental: MAT2203 Induction / SOC Consolidation
2 days IV AMB + 5FC followed by oral MAT2203 + 5FC for 12 days of induction therapy followed by 4 weeks of standard of care consolidation therapy
|
oral lipid nanocrystal amphotericin B
Other Names:
|
|
Active Comparator: SOC Induction / SOC Consolidation
Standard of care induction therapy (IV AMB + 5FC) followed by 4 weeks of standard of care consolidation therapy (fluconazole)
|
Intravenous Amphotericin B
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Survival
Time Frame: 2 weeks
|
All-cause mortality
|
2 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Meningitis-free survival
Time Frame: 10 weeks
|
Survival time without Cryptococcus culture-positive relapse of meningitis
|
10 weeks
|
|
Evidence of fungicidal activity
Time Frame: 2 weeks
|
Rate of CSF Cryptococcus clearance (early fungicidal activity [EFA])
|
2 weeks
|
|
CSF culture sterility
Time Frame: 10 weeks
|
cumulative incidence of CSF culture sterilization
|
10 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: David R Boulware, MD, University of Minnesota
- Principal Investigator: David B Meya, MBChB, Infectious Diseases Institute
Study record dates
Study Major Dates
Study Start (Anticipated)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Central Nervous System Diseases
- Nervous System Diseases
- Infections
- Central Nervous System Infections
- Bacterial Infections and Mycoses
- Mycoses
- Meningitis, Fungal
- Central Nervous System Fungal Infections
- Cryptococcosis
- Meningitis
- Meningitis, Cryptococcal
- Anti-Infective Agents
- Anti-Bacterial Agents
- Antifungal Agents
- Antiprotozoal Agents
- Antiparasitic Agents
- Amebicides
- Amphotericin B
- Liposomal amphotericin B
Other Study ID Numbers
Other Study ID Numbers
- MB-70018
- CTA 0217 (Other Identifier: Uganda National Drug Authority (NDA))
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.